Impact of Sustained RNAi-mediated Suppression of Cellular Cofactor Tat-SF1 on HIV-1 Replication in CD4+ T Cells
Overview
Affiliations
Background: Conventional anti-HIV drug regimens targeting viral enzymes are plagued by the emergence of drug resistance. There is interest in targeting HIV-dependency factors (HDFs), host proteins that the virus requires for replication, as drugs targeting their function may prove protective. Reporter cell lines provide a rapid and convenient method of identifying putative HDFs, but this approach may lead to misleading results and a failure to detect subtle detrimental effects on cells that result from HDF suppression. Thus, alternative methods for HDF validation are required. Cellular Tat-SF1 has long been ascribed a cofactor role in Tat-dependent transactivation of viral transcription elongation. Here we employ sustained RNAi-mediated suppression of Tat-SF1 to validate its requirement for HIV-1 replication in a CD4+ T cell-derived line and its potential as a therapeutic target.
Results: shRNA-mediated suppression of Tat-SF1 reduced HIV-1 replication and infectious particle production from TZM-bl reporter cells. This effect was not a result of increased apoptosis, loss of cell viability or an immune response. To validate its requirement for HIV-1 replication in a more relevant cell line, CD4+ SupT1 cell populations were generated that stably expressed shRNAs. HIV-1 replication was significantly reduced for two weeks (~65%) in cells with depleted Tat-SF1, although the inhibition of viral replication was moderate when compared to SupT1 cells expressing a shRNA targeting the integration cofactor LEDGF/p75. Tat-SF1 suppression was attenuated over time, resulting from decreased shRNA guide strand expression, suggesting that there is a selective pressure to restore Tat-SF1 levels.
Conclusions: This study validates Tat-SF1 as an HDF in CD4+ T cell-derived SupT1 cells. However, our findings also suggest that Tat-SF1 is not a critical cofactor required for virus replication and its suppression may affect cell growth. Therefore, this study demonstrates the importance of examining HIV-1 replication kinetics and cytotoxicity in cells with sustained HDF suppression to validate their therapeutic potential as targets.
Human Tat-specific factor 1 binds the HIV-1 genome and selectively transports HIV-1 RNAs.
Hulver M, Trautman J, Goodwin A, Roszczenko S, Fogarty K, Miller H Mol Biol Rep. 2020; 47(3):1759-1772.
PMID: 32016635 DOI: 10.1007/s11033-020-05267-z.
The therapeutic landscape of HIV-1 via genome editing.
Kwarteng A, Ahuno S, Kwakye-Nuako G AIDS Res Ther. 2017; 14(1):32.
PMID: 28705213 PMC: 5513397. DOI: 10.1186/s12981-017-0157-8.
Strobel B, Miller F, Rist W, Lamla T Hum Gene Ther Methods. 2015; 26(4):147-57.
PMID: 26222983 PMC: 4554548. DOI: 10.1089/hgtb.2015.051.
RNA interference approaches for treatment of HIV-1 infection.
Bobbin M, Burnett J, Rossi J Genome Med. 2015; 7(1):50.
PMID: 26019725 PMC: 4445287. DOI: 10.1186/s13073-015-0174-y.
Multiplexing seven miRNA-Based shRNAs to suppress HIV replication.
Choi J, Bharaj P, Abraham S, Ma H, Yi G, Ye C Mol Ther. 2014; 23(2):310-20.
PMID: 25358251 PMC: 4445613. DOI: 10.1038/mt.2014.205.